Corvus, ImmunityBio week’s top gainers on positive data: Clinical Report

Phase I proof-of-concept data sent shares of  Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) up 166%, marking the week’s biggest data-triggered stock move. The company said 75% of patients in the study achieved 75% skin clearance after receiving first-in-class oral ITK inhibitor, soquelitinib. The stock bump lifted its market cap to over $1.6 billion.

A trio of cancer readouts from ImmunityBio Inc. (NASDAQ:IBRX) sent that company’s shares up 9% last Tuesday and another 40% on Friday, bringing its market cap to about $3.8 billion. The updates, which came from ImmunityBio’s allogeneic CD19 NK cell therapy and its IL-15 fusion protein superagonist, were standouts at the J.P. Morgan Healthcare Conference.   ...